. Structure, design and production of a trimeric CD27L and pH stability of HERA-CD27L. (A) Schematic depiction of the structure of the trimeric CD27L. For engineering of the trimeric CD27L, one CD27L (CD70) protomer sub-sequence (called the CD27L-receptor binding domain or CD27L-RBD) was fused to a bacteriophage-derived trimerization domain (BDTD). (B) Purification was accomplished by a two-step process combining AFC followed by preparative SEC. For analytical SEC, purified trimeric CD27L was detected by online measurement of absorption at 214 nm. Content of monomer and aggregates was calculated as the AUC from the elution profile of the SEC. Trimeric CD27L eluted as a single peak and showed no detectable aggregates. (C) Purity and aggregation status of purified trimeric CD27L was also assessed by non-reducing and reducing SDS-PAGE. (D) pH stability was assessed by exposing purified HERA-CD27L to various pH buffers from pH 2.0 to pH 12.0. 24 hours after re-buffering, aliquots were taken and frozen at <-65°C prior to measuring ELISA binding to immobilized human CD27-Fc. Values are mean ± S.D. OD at a wavelength of 450 nm (with a 630 nm correction) normalized to binding of untreated HERA-CD27L. Representative data from at least three independent experiments are shown. 
